<DOC>
	<DOCNO>NCT02173717</DOCNO>
	<brief_summary>Study investigate whether extent suggest P-glycoprotein ( P-gp ) inducer rifampicin affect plasma exposure dabigatran .</brief_summary>
	<brief_title>Relative Bioavailability Single Doses Dabigatran Etexilate Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Healthy male female subject accord follow criterion : base upon complete medical history , include physical examination , vital sign ( BP , pulse rate ) , 12lead ECG , clinical laboratory test Age ≥18 Age ≤45 year Body Mass Index ( BMI ) ≥18.5 ≤29.9 kg/m2 Signed date write informed consent prior admission study accordance GCP local legislation Any gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder Subjects investigator 's judgement perceive increase risk bleeding , example : Hemorrhagic disorder bleed diathesis Occult blood faeces haematocryal Trauma surgery within last month long excessive risk bleeding persist event , plan surgery trial participation History arteriovenous malformation aneurysm History gastroduodenal ulcer disease , gastrointestinal haemorrhage , haemorrhoid History intracranial , intraocular , spinal , retroperitoneal , atraumatic intraarticular bleeding Use drug may interfere haemostasis trial conduct ( e.g . acetylic salicylic acid nonsteroidal antiinflammatory drug ) Relevant surgery gastrointestinal tract Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Use drug might reasonably influence result trial base knowledge time protocol preparation within four week prior administration trial , especially inhibitor inducer Pgp , CYP3A4 , CYP2C9 , CYP2C19 trial ( comment : CYP3A4 inhibitor example azole antimycotic , macrolides grapefruit juice , CYP3A inducers example St. John 's Wort certain anticonvulsant ) Intake medication , influence blood clotting , i.e . acetylsalicylic acid , nonsteroidal antirheumatic drug , cumarin , etc . within 14 day prior screen trial Participation another trial investigational drug within one month prior administration trial Alcohol abuse ( 60 g/day male , 40 g/day female ) Drug abuse Blood donation ( 100 mL within 4 week prior administration ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre Previous intake rifampicin For female subject : Pregnancy / positive pregnancy test , plan become pregnant study within 1 month study completion No adequate contraception woman childbearing potential Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>